Answers are grounded in this paper and cite their sources.
Introduction Pharmacy-service costing studies measure what services cost to deliver, and economic evaluations weigh their value to the payer, but to our knowledge none sets the revenue a pharmacy earns from a nursing home against its own costs. Aim To measure, from the community pharmacy's own perspective, the contribution margins of nursing-home supply and of its separable parts (the logistics layer of package handling and blistering, and medication review), and the effect of billing every medication review. Method Retrospective contribution-margin analysis of the largest client of one community pharmacy, a four-home group (373 beds) among the eight facilities it supplies, using 2024 operating data at 2025 prices and reported to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022. Staff cost was set per productive hour from the collective wage for experienced staff (€51.46/h pharmacist, €34.16/h technician). Outcomes were the contribution margin and the staff-cost ratio (SCR, staff cost as a share of gross margin, lower is better) against walk-in dispensing, with a billing-rate scenario (0–100%) and one-way sensitivity analyses. Results A home package took 3.25 times as much staff time as a walk-in package (0.166 vs 0.051 h). The SCR was 25.4% for walk-in dispensing and 77.4% for package handling, an upper bound because its hours include blistering. Medication review reached SCR 28.6%, close to walk-in dispensing, but none was billed in 2024. Packages and blistering gave a modelled annual contribution of €79,425. Billing every eligible review would add up to €30,893, reaching €110,317 (SCR 57.1%). The margin stayed positive across all one-way sensitivity analyses, from €69,846 to €89,003 at current practice. Without cost-centre accounting, shared overheads could not be assigned, so net profitability is uncertain. Conclusion At the contribution level, nursing-home supply with in-pharmacy multidose blistering is not inherently loss-making. Its weak point is the logistics layer (package handling and blistering), which the measured hours could not separate. Medication review is close to the walk-in benchmark but went unbilled. According to the pharmacy, the barrier is administrative. Whether home supply remains profitable after overheads could not be determined.
No takes yet. Share an insight, caveat, or question.
Riegel et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: